Tarsus Pharmaceuticals (TARS) Interest Expenses (2019 - 2026)

Tarsus Pharmaceuticals' Interest Expenses history runs 8 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• On a quarterly basis, Interest Expenses fell 3.84% year-over-year to $2.1 million in Q1 2026; TTM through Mar 2026 was $8.8 million, a 3.34% decrease from a year earlier, with the FY2025 full-year figure at $312.6 million, up 73.05% from the prior year.
• Interest Expenses retreated to $2.1 million in Q1 2026 per TARS's latest filing, from $2.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $105.7 million in Q2 2025 and bottomed at $168000.0 in Q4 2022.
• The 5-year median for Interest Expenses is $989000.0 (2023), against an average of $7.5 million.
• Biggest YoY gain for Interest Expenses was 4913.51% in 2025; the steepest drop was 7.24% in 2025.
• Year by year, Interest Expenses stood at $168000.0 in 2022, then jumped by 488.69% to $989000.0 in 2023, then surged by 138.73% to $2.4 million in 2024, then retreated by 6.23% to $2.2 million in 2025, then slipped by 3.88% to $2.1 million in 2026.
• Per Business Quant, the three latest TARS Interest Expenses figures stand at $2.1 million (Q1 2026), $2.2 million (Q4 2025), and $2.3 million (Q3 2025).